-
In re: Bendamustine ('524) Patent Litigation DC CAFC
- 1:13-cv-02046
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 12/19/2013
- Closed: 06/29/2017
- Latest Docket Entry: 01/25/2019
- PACER
- Docket updated daily
1
Plaintiff
35
Defendants
1
Accused
Product
4
Patents-in-Suit
1,289
Days in
Litigation
-
In re: Bendamustine ('524) Patent Litigation DC CAFC
- 1:13-cv-02046
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 12/19/2013
- Closed: 06/29/2017
- Latest Docket Entry: 01/25/2019
- PACER
- Docket updated daily
Causes of Action
Infringement
Willful Patent Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A vial containing a reconstituted solution of bendamustine hydrochloride and mannitol in sterile water for injection, wherein the ratio by weight of bendamustine hydrochloride to mannitol in the vial is 15:25.5, and wherein the bendamustine
view more
|
Enforceable and Valid (103)
Entry 506 Entry 472 |
| 4 |
A 20 mL vial containing 100 mg of bendamustine hydrochloride and 170 mg of mannitol reconstituted in sterile water for injection.
|
Enforceable and Valid (103)
Entry 506 Entry 472 |
-
Infringement
Emcure Pharmaceuticals Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 100 mg bendamustine hydrochloride for injection25 mg bendamustine hydrochloride for injection | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 100 mg bendamustine hydrochloride for injection25 mg bendamustine hydrochloride for injection | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
Emcure Pharmaceuticals USA, Inc.
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 100 mg bendamustine hydrochloride for injection25 mg bendamustine hydrochloride for injection | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 100 mg bendamustine hydrochloride for injection25 mg bendamustine hydrochloride for injection | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
Hospira Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 100 mg/vial25 mg/vial Bendamustine Hydrochloride Powder for Infusion | US 8,609,863 B2 |
1
|
Infringement
Entry 506
|
| 100 mg/vial25 mg/vial Bendamustine Hydrochloride Powder for Infusion | US 8,895,756 B2 |
1, 4
|
Infringement
Entry 506
|
Wockhardt Bio AG
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial Bendamustine Hydrochloride Powder for Infusion purusant to ANDA No. 207149 | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial Bendamustine Hydrochloride Powder for Infusion purusant to ANDA No. 207149 | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 16
|
Wockhardt Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial Bendamustine Hydrochloride Powder for Infusion purusant to ANDA No. 207149 | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial Bendamustine Hydrochloride Powder for Infusion purusant to ANDA No. 207149 | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 16
|
Wockhardt USA LLC
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial Bendamustine Hydrochloride Powder for Infusion purusant to ANDA No. 207149 | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 16
|
| 25 mg/vial, 100 mg/vial Bendamustine Hydrochloride Powder for Infusion purusant to ANDA No. 207149 | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 16
|
